HCV Tappt Adherence Study

Last updated: April 7, 2025
Sponsor: University of Illinois at Chicago
Overall Status: Active - Recruiting

Phase

N/A

Condition

Liver Disorders

Hepatitis

Treatment

Use of Tappt App

Clinical Study ID

NCT06263829
2023-1580
  • Ages > 18
  • All Genders

Study Summary

The goal of this non-inferiority clinical trial is to evaluate the efficacy of Tappt, a novel digital medication companion solution, among individuals with hepatitis C virus (HCV) who are starting a daily oral medication regimen following standard of care in a clinical pharmacy setting.

  • The primary aim is to assess the non-inferiority of Tappt with medication adherence, treatment completion, sustained virologic response (SVR) assessment, and SVR achievement rates.

  • The secondary aim is to assess the efficacy of Tappt at enabling pharmacists to personalize treatment and management decision based on participants' reported barriers to adherence, care, and SVR achievement.

Participants will download and utilize the Tappt app to record adherence to oral medication. For the purposes of this study, adherence for participants in the intervention arm will be measured using a modified medication possession ratio (MPR) measure called medication tag scan ratio (MTSR). MTSR is defined as a percentage of the number of times participants scanned their passive tags versus the total of expected tag scans based on that participant's medication regimen and treatment period.

Upon study completion, a retrospective matched control will be established for the intervention group. Historic data for the matched control's adherence, treatment completion, SVR assessment, and SVR rates will be compared to the intervention arm.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. 18 years of age or older

  2. Hepatitis C virus (HCV) infection (denoted by positive HCV antibody and detectableHCV RNA)

  3. Initiating oral HCV therapy with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir

  4. HCV treatment provided and managed by the clinical pharmacist at UI Health

  5. Access to a mobile smartphone (iPhone 7 or later; Android release date 2012 orlater) with reliable data and/or Wi-Fi access

  6. Ability to verbalize understanding of the study protocol in English

  7. Able and willing to provide informed consent in English

Exclusion

Exclusion Criteria:

  1. Inability to speak and read English

  2. Inability or unwillingness to adhere to the study protocol

  3. Pregnant individuals

  4. Decompensated cirrhosis (Child Turcotte Pugh Class B and C); hepatocellularcarcinoma; prior liver or kidney transplant

No patient will be excluded because of gender, race or ethnic origin.

The following populations will be excluded from the study:

  • Adults 18 years of age and older who are unable or unwilling to consent

  • Individuals less than 18 years old

  • Pregnant individuals

  • Prisoners

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Use of Tappt App
Phase:
Study Start date:
June 01, 2024
Estimated Completion Date:
April 01, 2026

Connect with a study center

  • UIH

    Chicago, Illinois 60612
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.